{
    "clinical_study": {
        "@rank": "106069", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "MenABCWY"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Active Comparator", 
                "description": "MenACWY"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the effectiveness of 2 doses of MenABCWY vaccine in adolescents compared to a\n      single dose of MenACWY vaccine."
        }, 
        "brief_title": "Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adolescents from 10-18 years of age, generally in good health, and available for all\n             study visits, who/whose legally acceptable representative has given written informed\n             consent at the time of enrollment.\n\n          -  Female subjects of childbearing potential must have a negative urine pregnancy test.\n\n        Exclusion Criteria:\n\n          -  Serious, acute, or chronic illnesses. Previous or suspected disease caused by N.\n             meningitidis. Previous immunization with any meningococcal vaccine.\n\n          -  Exposure to individuals with clinically proven meningococcal disease or clinical\n             bacterial meningitis without further microbiologic characterization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140762", 
            "org_study_id": "V102_16"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "Effectiveness", 
                "intervention_name": "MenABCWY", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "Effectiveness", 
                "intervention_name": "MenACWY", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Meningitis ABCWY", 
            "adolescents", 
            "accination", 
            "meningococcal disease"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35802"
                    }, 
                    "name": "Accelovance, Inc"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jonesboro", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72401"
                    }, 
                    "name": "The Children's Clinic of Jonesboro, P.A."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32935"
                    }, 
                    "name": "Accelovance, Inc"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newton", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67114"
                    }, 
                    "name": "Heartland Research Associates LLC"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67207"
                    }, 
                    "name": "Heartland Research Associates, LLC"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40291"
                    }, 
                    "name": "Bluegrass Clinical Research, Inc."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68134"
                    }, 
                    "name": "Meridian Clinical Research"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44121"
                    }, 
                    "name": "Senders Pediatrics"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "+1 800 244 7668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentages of  N. meningitidis serogroup B invasive disease strains killed at 1:4 and 1:8 dilutions, for each subject", 
                "safety_issue": "No", 
                "time_frame": "1 Month after 2-Dose vaccination Series"
            }, 
            {
                "measure": "Percentages of N. meningitidis serogroup B invasive disease strains killed at 1:4 and 1:8 dilutions, for each subject", 
                "safety_issue": "No", 
                "time_frame": "4 Months after 2-dose Vaccination Series"
            }, 
            {
                "measure": "percentages of subjects with hSBA \u2265 1:4 and hSBA titer \u2265 1:8 against four N. meningitidis serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "1 Month after 2-Dose vaccination Series"
            }, 
            {
                "measure": "percentages of subjects with hSBA \u2265 1:4 and hSBA titer \u2265 1:8 against four N. meningitidis serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "4 Months after 2-Dose Vaccination Series"
            }, 
            {
                "measure": "percentages of subjects with hSBA titers against serogroup B test strains \u2265LLQ, \u22655, \u22658, \u226516, \u226532, \u226564, \u2265128", 
                "safety_issue": "No", 
                "time_frame": "one month after 2-dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with hSBA titers against serogroup B test strains \u2265LLQ, \u22655, \u22658, \u226516, \u226532, \u226564, \u2265128", 
                "safety_issue": "No", 
                "time_frame": "four Months after 2-dose vaccination series"
            }
        ], 
        "reference": [
            {
                "PMID": "12531326", 
                "citation": "Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003 Jan 30;21(7-8):605-10. PubMed"
            }, 
            {
                "PMID": "21615224", 
                "citation": "Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011 Jul;11(7):969-85. doi: 10.1517/14712598.2011.585965. Epub 2011 May 26. Review. PubMed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events and other indicators of reactogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to 6 months."
            }, 
            {
                "measure": "percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "one month after 2-dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "Four months after 2-dose vaccination series"
            }, 
            {
                "measure": "hSBA Geometric Mean Titers against serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "one month after 2-dose vaccination series"
            }, 
            {
                "measure": "hSBA Geometric Mean Titers against serogroup B test strains", 
                "safety_issue": "No", 
                "time_frame": "Four months after 2-dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with hSBA titers \u2265 LLQ, \u22655, \u22658, \u226516, \u226532, \u226564, \u2265128 against serogroups A, C, W, Y", 
                "safety_issue": "No", 
                "time_frame": "one month after 2-dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with hSBA titers \u2265 LLQ, \u22655, \u22658, \u226516, \u226532, \u226564, \u2265128 against serogroups A, C, W, Y", 
                "safety_issue": "No", 
                "time_frame": "Four Months after 2-Dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "One month after 2-dose vaccination series"
            }, 
            {
                "measure": "percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "Four months after 2-Dose vaccination Series"
            }, 
            {
                "measure": "hSBA Geometric Mean Titers to serogroups A, C, W, and Y", 
                "safety_issue": "No", 
                "time_frame": "One month after 2-dose vaccination series"
            }, 
            {
                "measure": "hSBA Geometric Mean Titers to serogroups A, C, W, and Y", 
                "safety_issue": "No", 
                "time_frame": "Four Months after 2-dose vaccination series"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}